Kinapse is the world leader in the provision of outsourced regulatory and compliance services to the life sciences industry.
Kinapse counts many of the world’s largest life sciences companies and regulatory organisations as customers including Pfizer, GSK, Merck Serono, Johnson & Johnson and the European Medicines Agency. Kinapse operates a unique blended onshore-offshore resourcing model enabling the Business to offer customers cost effective off-shore solutions allied to input from industry leading consultants based in the UK. The Group has offices in the UK, India and the United States.
Synova Capital has invested alongside Kinapse’s CEO, Andy Black, in order to support the management team’s growth strategy.
- 62%Revenue growth
- 400+Jobs created
- 16.1xCost multiple on exit
- Sector: Business Services
- Investment Date: Sept 2012
- Website: www.kinapse.com
Chief Executive – Kinapse
“We have had a fantastic partnership with Synova which has been instrumental in building Kinapse to its successful position today. The entire Synova team has been a pleasure to work with and I have found their strategic counsel and operational discipline to be particularly valuable. As a result, I wholeheartedly recommend Synova as an investment partner to ambitious CEO’s of growth businesses.”
Founded by Andy Black, CEO, Kinapse is a leading provider of outsourced and consultancy services to the global life sciences industry. Andy has successfully grown the business over a number of years and our growth capital investment has provided management with a new investment partner committed to funding the company’s future expansion.
In recent years the management team has successfully grown the business by expanding the outsourcing and consultancy services provided to the global life sciences industry. We were attracted to the business as a result of our belief that this sector will continue to outsource services to specialist providers such as Kinapse. Synova will be supporting and securing the future development of the business with further capital, strategic support and access to our network.
Synova instituted financial and trade buyer engagment programmes during our period of ownership; we successfully exited Kinapse to Hg Capital following a targeted and highly competitive auction process during January 2016 returning 16.1x cost and 126% IRR.